What's new

RSS
Date Content
31/08/2018 News and press releases: Development of medicines for rare diseases
31/08/2018 Human medicines European public assessment report (EPAR): Pixuvri, pixantrone dimaleate, Lymphoma, Non-Hodgkin, 10/05/2012, Additional monitoring, Conditional approval, 18, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, 12/01/2005, 50, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, 14/02/1996, 30, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin, linagliptin, Diabetes Mellitus, Type 2, 11/11/2016, Additional monitoring, 4, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Colobreathe, Colistimethate sodium, Cystic Fibrosis, 13/02/2012, 9, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Luveris, lutropin alfa, Ovulation Induction, Infertility, Female, 29/11/2000, 19, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Cystagon, mercaptamine bitartrate, Cystinosis, 23/06/1997, 14, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Ciambra, pemetrexed disodium hemipentahydrate, Carcinoma, Non-Small-Cell Lung, Mesothelioma, 02/12/2015, Generic, 2, Authorised
31/08/2018 Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Peripheral Vascular Diseases, Acute Coronary Syndrome, 03/12/2010, 11, Authorised